SABCS 2025 | Challenges and future directions of ADC targets and payloads in breast cancer
Francois Poumeaud, MD, Oncopole Claudius Regaud, Toulouse, France, comments on the challenges of comparing different antibody-drug conjugates (ADCs) in breast cancer due to the lack of comprehensive data, but suggests that changing the target or payload may bring additional benefits. Dr Poumeaud additionally highlights the current limitations of ADC development, which is mostly based on topoisomerase-1 inhibitors, and expresses hope for future advancements that will allow for more flexibility in changing targets and payloads. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2025 Meeting in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So one million dollar question, I guess. To date, we have no data to compare in a comparison between all ADCs. So that’s really difficult to answer. But if we base our results on the A3 study that was published last year by Dr. Abelman, we can see that sometimes changing the target can bring an additional benefit as compared to having the same payload. Hopefully, one day we will have ADCs with different targets and different payloads at the same time...
So one million dollar question, I guess. To date, we have no data to compare in a comparison between all ADCs. So that’s really difficult to answer. But if we base our results on the A3 study that was published last year by Dr. Abelman, we can see that sometimes changing the target can bring an additional benefit as compared to having the same payload. Hopefully, one day we will have ADCs with different targets and different payloads at the same time. It will be really easy when someone is going to progress with an anti-Trop2 and anti-topoisomerase 1 ADC, maybe to change all the target or both payload and target. But unfortunately, for now, the ADC development is based mostly on topoisomerase-1 inhibitors. So we’ll have to change the target. We will have definitely to change the payload first, but it will depend on the molecules that we will have.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
